Charles River Laboratories International, INC.: management transactions · United States · SEC (Form 4)

About Charles River Laboratories International, INC.

Charles River Laboratories International, Inc. (ticker: CRL) is a U.S.-based company listed on the NYSE (New York Stock Exchange) in the United States. For French-, Belgian- and Swiss-based investors, it represents a core life-sciences services and tools business, positioned early in the pharmaceutical value chain and therefore leveraged to R&D spending by pharma companies, biotech firms, government agencies, and academic institutions. The company traces its origins to 1947, when it began as a one-person laboratory in Boston overlooking the Charles River. Its headquarters was later relocated to Wilmington, Massachusetts, where it remains today, and the group has evolved into a global strategic partner supporting discovery, early development, and certain manufacturing activities. ([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai)) Charles River’s business model is built around several complementary operating lines. Research Models and Services provides laboratory animal models, including rodent models, together with related services that support basic and translational research. Discovery and Safety Assessment offers preclinical services such as pharmacology, toxicology, pathology, safety assessment, and regulatory support. The company also has manufacturing- and insourcing-oriented capabilities, supporting biologics and development workflows; however, in 2026 it announced a definitive agreement to divest its CDMO and Cell Solutions businesses, indicating a sharper strategic focus on its higher-value scientific platforms. Overall, the company is positioned as an integrated early-stage drug development partner rather than a pure-play CRO or a standalone laboratory-animal supplier. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-third-quarter-2025-results?utm_source=openai)) From a competitive standpoint, Charles River benefits from deep scientific expertise, a long operating history, and a broad international footprint. The company says it operates more than 130 facilities across 30 countries, giving it reach across North America, Europe, and Asia and allowing it to serve global pharmaceutical and biotech clients with local execution. That scale, combined with its breadth across discovery, preclinical safety, and research models, supports its relevance in a highly fragmented but quality-sensitive market. ([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai)) Recent developments matter for the investment case. In February 2026, Charles River reported full-year 2025 revenue of $4.02 billion, slightly below the prior year, while highlighting improved non-GAAP margin performance driven by restructuring and cost actions. In May 2026, the company announced continued momentum in its digital pathology platform, describing an AI-enabled end-to-end workflow designed to shorten study timelines and improve pathologist efficiency. Management has also been actively reshaping the portfolio, as shown by the planned divestiture of the CDMO and Cell Solutions businesses to GI Partners. These moves suggest a management team focused on simplification, margin discipline, and concentration on differentiated science. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-fourth-quarter-and-full-14/?utm_source=openai))